Back to Stocks

ARVN

ARVINAS, INC.
2 filings tracked
healthcarebiotechnologyMID ($2B-10B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Arvinas has achieved a watershed moment in biotechnology with the FDA approval of VEPPANU (vepdegestrant), the first-ever approved PROTAC protein degrader.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the headline approval of VEPPANU, the underlying financials reveal a company struggling to transition from a research entity to a commercial success.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every ARVN filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The latest 10-Q presents a company at a critical inflection point, transitioning from a pure-play R&D shop to a licensed commercial entity. The FDA approval of VEPPANU provides the necessary proof-of-concept for the PROTAC modality, but the financial statements highlight the precarious nature of this transition. The massive drop in quarterly revenue underscores the volatility of collaboration-based income and the urgency of the company's need to convert its scientific success into a sustainable cash flow stream. Investors are now faced with a trade-off between the validation of a first-in-class platform and the execution risks of a third-party commercialization strategy. While the balance sheet is currently robust, the ability of Arvinas to maintain its runway depends on the speed of its next partnership deal and the successful resolution of clinical holds. The coming months will determine if VEPPANU is a true commercial catalyst or merely a regulatory milestone in a continuing cycle of cash burn.

Selected Quarter

Core Takeaway

Arvinas has moved from a theoretical platform to a commercially approved company, but it lacks its own sales infrastructure, making the selection of a commercial partner the next critical value driver.

Investor Lens

The trade-off is between the scientific derisking of the platform versus the commercial execution risk of a partner-led launch.

Watch Next

The announcement of the third-party commercial partner for VEPPANU and the lifting of the clinical hold on ARV-102.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.11Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 11

FDA approval of VEPPANU as the first-ever PROTAC protein degrader.

regulatory action
95%
bearishMay 11

Quarterly revenue declined 92% year-over-year to $15.6 million.

earnings miss
80%
bearishMay 11

Continued high operating burn with a net loss of $57.6 million for the quarter.

margin compression
60%
neutralMay 11

Appointment of Randy Teel as President and CEO.

management change
40%
bullishMay 11

FDA approval of VEPPANU as the first-ever PROTAC protein degrader.

regulatory action
95%
bearishMay 11

Quarterly revenue declined 92% year-over-year to $15.6 million.

earnings miss
80%
bearishMay 11

Continued high operating burn with a net loss of $57.6 million for the quarter.

margin compression
60%
neutralMay 11

Appointment of Randy Teel as President and CEO.

management change
40%

Filing History

10-QMay 11, 2026
Expand Sequence

The latest 10-Q presents a company at a critical inflection point, transitioning from a pure-play R&D shop to a licensed commercial entity. The FDA approval of VEPPANU provides the necessary proof-of-concept for the PROTAC modality, but the financial statements highlight the precarious nature of this transition. The massive drop in quarterly revenue underscores the volatility of collaboration-based income and the urgency of the company's need to convert its scientific success into a sustainable cash flow stream. Investors are now faced with a trade-off between the validation of a first-in-class platform and the execution risks of a third-party commercialization strategy. While the balance sheet is currently robust, the ability of Arvinas to maintain its runway depends on the speed of its next partnership deal and the successful resolution of clinical holds. The coming months will determine if VEPPANU is a true commercial catalyst or merely a regulatory milestone in a continuing cycle of cash burn.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.